Janice E Graham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5423608/publications.pdf

Version: 2024-02-01

279798 155660 3,232 80 23 55 citations g-index h-index papers 83 83 83 3637 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet, The, 1997, 349, 1793-1796.	13.7	893
2	Frailty, fitness and late-life mortality in relation to chronological and biological age. BMC Geriatrics, 2002, 2, 1.	2.7	560
3	Five-Year Follow-up of Cognitive Impairment With No Dementia. Archives of Neurology, 2003, 60, 577.	4.5	190
4	Standardization of the Diagnosis of Dementia in the Canadian Study of Health and Aging. Neuroepidemiology, 1996, 15, 246-256.	2.3	126
5	The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good. BMJ Global Health, 2022, 7, e008684.	4.7	122
6	Understanding Vaccine Hesitancy in Canada: Results of a Consultation Study by the Canadian Immunization Research Network. PLoS ONE, 2016, 11, e0156118.	2.5	121
7	The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurology, 2007, 7, 26.	1.8	90
8	Assessment of factors associated with complete immunization coverage in children aged 12-23 months: a cross-sectional study in Nouna district, Burkina Faso. BMC International Health and Human Rights, 2009, 9, S10.	2.5	86
9	Actor-Network Theory: a tool to support ethical analysis of commercial genetic testing. New Genetics and Society, 2003, 22, 271-296.	1.2	85
10	Global challenges of implementing human papillomavirus vaccines. International Journal for Equity in Health, 2011, 10, 27.	3.5	48
11	Reciprocal relations: The recognition and co-construction of caring with Alzheimer's disease. Journal of Aging Studies, 2006, 20, 335-349.	1.4	43
12	The Rate of Decline in Function in Alzheimer's Disease and Other Dementias. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 1999, 54, M65-M69.	3.6	39
13	Technologies of trust in epidemic response: openness, reflexivity and accountability during the 2014–2016 Ebola outbreak in West Africa. BMJ Global Health, 2019, 4, e001272.	4.7	38
14	Patterns and Health Effects of Caring for People With Dementia: The Impact of Changing Cognitive and Residential Status. Gerontologist, The, 2002, 42, 643-652.	3.9	37
15	Capacity for a global vaccine safety system: The perspective of national regulatory authorities. Vaccine, 2012, 30, 4953-4959.	3.8	37
16	Qualitative Analysis of the Clinician Interview-Based Impression of Change (Plus): Methodological Issues and Implications for Clinical Research. International Psychogeriatrics, 2000, 12, 403-413.	1.0	36
17	Anthropological contributions to the understanding of age-related cognitive impairment. Lancet Neurology, The, 2005, 4, 320-326.	10.2	33
18	Risk, choice and the â€~girl vaccine': Unpacking human papillomavirus (HPV) immunisation. Health, Risk and Society, 2012, 14, 57-69.	1.7	31

#	Article	IF	CITATIONS
19	Dynamics of Cognitive Aging: Distinguishing Functional Age and Disease from Chronologic Age in a Population. American Journal of Epidemiology, 1999, 150, 1045-1054.	3.4	30
20	Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opinion on Pharmacotherapy, 2006, 7, 119-133.	1.8	28
21	Memorabilities: enduring relationships, memories and abilities in dementia. Ageing and Society, 2007, 27, 533-554.	1.7	27
22	Multigenic Control of Drug Response and Regulatory Decision-Making in Pharmacogenomics: The Need for an Upper-Bound Estimate of Genetic Contributions. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2005, 3, 53-71.	0.3	26
23	Mild Cognitive Impairment: Ethical Considerations for Nosological Flexibility in Human Kinds. Philosophy, Psychiatry and Psychology, 2006, 13, 31-43.	0.4	26
24	From discovery to delivery: public sector development of the <i>r</i> VSV-ZEBOV Ebola vaccine. Journal of Law and the Biosciences, 2020, 7, lsz019.	1.6	25
25	Royal society of Canada COVID-19 report: Enhancing COVID-19 vaccine acceptance in Canada. Facets, 2021, 6, 1184-1246.	2.4	25
26	Standardization and Omics Science: Technical and Social Dimensions Are Inseparable and Demand Symmetrical Study. OMICS A Journal of Integrative Biology, 2010, 14, 327-332.	2.0	24
27	Factors Associated with Inconsistent Diagnosis of Dementia Between Physicians and Neuropsychologists. Journal of the American Geriatrics Society, 1999, 47, 1294-1299.	2.6	22
28	Stigma and blame related to COVID-19 pandemic: A case-study of editorial cartoons in Canada. Social Science and Medicine, 2022, 296, 114803.	3.8	21
29	Are Canadians Providing Advance Directives about Health Care and Research Participation in the Event of Decisional Incapacity?. Canadian Journal of Psychiatry, 2011, 56, 209-218.	1.9	19
30	Smart Regulation: Will the government's strategy work?. Cmaj, 2005, 173, 1469-1470.	2.0	15
31	Challenges to immunization: the experiences of homeless youth. BMC Public Health, 2012, 12, 338.	2.9	15
32	Perinatal health care providers' approaches to recommending and providing pertussis vaccination in pregnancy: a qualitative study. CMAJ Open, 2020, 8, E377-E382.	2.4	15
33	Prebunking messaging to inoculate against COVID-19 vaccine misinformation: an effective strategy for public health. Journal of Communication in Healthcare, 2022, 15, 232-242.	1.5	15
34	Prevalence of Cognitive Impairment and Dementia as Defined by Neuropsychological Test Performance. Neuroepidemiology, 2000, 19, 121-129.	2.3	14
35	Harbinger of Hope or Commodity Fetishism: "Re-cognizing―Dementia in an Age of Therapeutic Agents. International Psychogeriatrics, 2001, 13, 131-134.	1.0	14
36	Ambiguous Capture: Collaborative Capitalism and the Meningitis Vaccine Project. Medical Anthropology: Cross Cultural Studies in Health and Illness, 2016, 35, 419-432.	1.2	14

#	Article	IF	Citations
37	Prepared for the â€~unexpected'? Lessons from the 2014–2016 Ebola epidemic in West Africa on integrating emergent theory designs into outbreak response. BMJ Global Health, 2018, 3, e000990.	4.7	14
38	Symptoms and Signs in Dementia Synergy and Antagonism. Dementia and Geriatric Cognitive Disorders, 1996, 7, 331-335.	1.5	12
39	Facilitating Regulation: The Dance of Statistical Significance and Clinical Meaningfulness in Standardizing Technologies for Dementia. BioSocieties, 2008, 3, 241-263.	1.3	12
40	Comfort with proxy consent to research involving decisionally impaired older adults: do type of proxy and risk-benefit profile matter?. International Psychogeriatrics, 2011, 23, 1479-1488.	1.0	12
41	Exploring the post-genomic world: differing explanatory and manipulatory functions of post-genomic sciences. New Genetics and Society, 2016, 35, 49-68.	1.2	11
42	Ebola vaccine innovation: a case study of pseudoscapes in global health. Critical Public Health, 2019, 29, 401-412.	2.4	11
43	A public health timeline to prepare for COVID-19 vaccines in Canada. Canadian Journal of Public Health, 2020, 111, 945-952.	2.3	11
44	Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19. International Journal of Health Services, 2021, 51, 5-13.	2.5	11
45	Vector Diagnostics in Dementia Derived from Bayes' Theorem. American Journal of Epidemiology, 1997, 146, 665-671.	3.4	10
46	Techniques for knowledge discovery in existing biomedical databases Estimation of individual aging effects in cognition in relation to dementia. Journal of Clinical Epidemiology, 2003, 56, 116-123.	5.0	10
47	Is consent for research genuinely informed? Using decision aid tools to obtain informed consent in the global south. Journal of Global Ethics, 2011, 7, 349-359.	0.5	9
48	Regulating prescription drugs for patient safety: Does Bill C-17 go far enough?. Cmaj, 2014, 186, E287-E292.	2.0	9
49	Developing product label information to support evidence-informed use of vaccines in pregnancy. Vaccine, 2019, 37, 7138-7146.	3.8	9
50	Immunization governance: Mandatory immunization in 28 Global NITAG Network countries. Vaccine, 2020, 38, 7258-7267.	3.8	9
51	From sandbox to pandemic: Agile reform of Canadian drug regulation. Health Policy, 2021, 125, 1115-1120.	3.0	9
52	Multiple institutional rationalities in the regulation of health technologies: an ethnographic examination. Science and Public Policy, 2009, 36, 445-455.	2.4	8
53	Asymmetry in Scientific Method and Limits to Cross-Disciplinary Dialogue. Journal of Investigative Medicine, 2007, 55, 130-141.	1.6	6
54	Race as a variable in pharmacogenomics science: from empirical ethics to publication standards. Pharmacogenetics and Genomics, 2008, 18, 837-841.	1.5	6

#	Article	IF	Citations
55	Substitute consent practices in the face of uncertainty: a survey of Canadian researchers in aging. International Psychogeriatrics, 2013, 25, 1821-1830.	1.0	6
56	Is physician dismissal of vaccine refusers an acceptable practice in Canada? A 2018 overview. Paediatrics and Child Health, 2019, 24, 92-97.	0.6	6
57	Vaccination discourses among chiropractors, naturopaths and homeopaths: A qualitative content analysis of academic literature and Canadian organizational webpages. PLoS ONE, 2020, 15, e0236691.	2.5	6
58	An Algorithmic Approach to the Differential Diagnosis of Dementia. Dementia and Geriatric Cognitive Disorders, 1996, 7, 324-330.	1.5	5
59	Rendre évidentÂ: une approche symétrique de la réglementation des produits thérapeutiques. Sociologie Et Sociétés, 0, 42, 153-180.	0.1	5
60	Governing off-label vaccine use: An environmental scan of the Global National Immunization Technical Advisory Group Network. Vaccine, 2020, 38, 1089-1095.	3.8	5
61	Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19. Journal of Law and the Biosciences, 2020, 7, Isaa083.	1.6	5
62	Under consent: participation of people with HIV in an Ebola vaccine trial in Canada. BMC Medical Ethics, 2021, 22, 42.	2.4	4
63	Healthcare providers' interpretations of product labelling information developed through a consensus stakeholder approach. Vaccine, 2021, 39, 2652-2659.	3.8	4
64	Faster Access to New Drugs: Fault Lines Between Health Canada's Regulatory Intent and Industry Innovation Practices. Ethics in Biology, Engineering & Medicine, 2013, 4, 231-239.	0.1	4
65	Genetically Modified Organisms as Public Goods: Plant Biotechnology Transfer in Colombia. Culture and Agriculture, 2009, 31, 26-38.	0.2	3
66	Knowledge Translation: Moving Proteomics Science to Innovation in Society. OMICS A Journal of Integrative Biology, 2016, 20, 352-361.	2.0	3
67	Modeling Decline in Alzheimer's Disease. International Psychogeriatrics, 1999, 11, 211-213.	1.0	2
68	Deferring Risk: Limitations to the Evidence in Product Labels for Vaccine Use in Pregnancy. Journal of Women's Health, 2022, 31, 1103-1112.	3.3	2
69	COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER). Vaccine, 2021, 39, 2504-2505.	3.8	1
70	" <i>I don't think there's a point for me to discuss it with my patientsâ€</i> : exploring health care providers' views and behaviours regarding COVID-19 vaccination. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	1
71	Just Evidence: Opening Health Knowledge to a Parliament of Evidence. , 2016, , 325-350.		0
72	How Do Postgenomic Innovations Emerge? Building Legitimacy by Proteomics Standards and Informing the Next-Generation Technology Policy. OMICS A Journal of Integrative Biology, 2019, 23, 406-415.	2.0	0

#	Article	IF	CITATIONS
73	Strengthening vaccination frameworks: Findings of a study on the legal foundations of National Immunization Technical Advisory Groups (NITAGs). Vaccine, 2020, 38, 840-846.	3.8	O
74	Ethics check-up of public health immunization programs in Canada. Canada Communicable Disease Report, 2021, 47, 237-241.	1.3	0
75	Lueurs et leurres de la santé globale. Anthropologie & Développement, 2017, , 213-234.	0.0	O
76	North End Community Health Centre in Halifax, NS: Relationship-based care goes beyond collaborative care to address patient needs. Canadian Family Physician, 2019, 65, e344-e355.	0.4	0
77	Title is missing!. , 2020, 15, e0236691.		O
78	Title is missing!. , 2020, 15, e0236691.		0
79	Title is missing!. , 2020, 15, e0236691.		0
80	Title is missing!. , 2020, 15, e0236691.		0